tissue analysis News
-
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, ...
-
Announcement – Total Shoulder Arthroplasty (TSA) Planning Through MRI Scan
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new tool for Total Shoulder Arthroplasty (TSA) planning. This tool performs segmentation of the shoulder bones from shoulder MRI scan, which is usually performed in shoulder healthcare. The segmentation output undergoes super-resolution enhancement to ...
By RSIP Vision
-
AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
-
Arterys Partners With Cercare Medical to Offer Advanced Perfusion Brain CT and MR Imaging Analysis Accelerating Access to Deep, Fast, and Reliable Insights
SAN FRANCISCO, November 29, 2021 (Newswire.com) - Arterys, the world's leading vendor-neutral AI platform, today announced its partnership with Cercare Medical to make their AI-powered imaging solution, Cercare Perfusion, available on the Arterys Platform. Arterys has fully integrated the Cercare Perfusion solution which will be available via its FDA-cleared and CE marked MICA platform to its ...
By Arterys Inc.
-
Avelas Welcomes Susan Stimson to its Board of Directors
SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company. “Susan brings an exceptional background and skillset to the Avelas Board. She has had incredible success throughout her career and her knowledge and experiences ...
-
Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium
SAN DIEGO, December 4, 2018 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, presented the initial results of the first part of its Phase II clinical trial in a poster session at this week’s San Antonio Breast Cancer Symposium (SABCS). The poster, titled “Use of a fluorescent activatable cell penetrating peptide ...
-
Full-Scale PROTAC In Vivo Evaluation Services to Facilitate PROTAC Drug R&D
In the process of drug development, the evaluation of drug effectiveness is one of the keys to determining whether prodrugs can sufficiently reach the market stage. BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC ...
By BOC Sciences
-
BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
-
Avalon Healthcare Solutions’ Client BCBS of South Carolina Adds CDx Diagnostics as In-Network Lab
CDx Diagnostics, Inc. is pleased to announce that it has signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions, Inc. of Tampa, Fla. The agreement means that CDx will be an in-network specialty anatomic pathology laboratory of Avalon client BlueCross BlueShield of South Carolina, and builds on Avalon’s positive medical policy for CDx’s proprietary ...
-
OncoDNA provides strategic support in Radiomics` prospective clinical trial SALMON
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical images with ...
By OncoDNA S.A.
-
Guided Therapeutics Turkish Distributor Doubles Order for LuViva Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has received an increased order for disposable Cervical Guides from the Turkish Ministry of Health (MOH). The order has more than doubled to 1.1 million disposable Cervical Guides from a ...
-
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva Advanced Cervical Scan Premarket Approval Application
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan. The LuViva is designed to detect cervical ...
-
Guided Therapeutics Ships First Four LuViva Advanced Cervical Scans for $14 million Turkish Ministry of Health Order
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva® Advance Cervical Scan units to its Turkish distributor for its order with the Turkish Ministry of Health (MOH). In total, the company plans to ship 25 LuViva units and 40,000 disposable Cervical ...
-
Biostage Hires David Green as Chief Executive Officer
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green as its Chief Executive Officer and appointed Mr. Green as Chairman of the Board of Directors (the ...
-
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy 40% of patients experienced exceptional responses lasting at least three ...
By Exscientia
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you